ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY
    3.
    发明申请
    ANTIMICROBIAL AGENTS AND THEIR USE IN THERAPY 审中-公开
    抗菌药物及其在治疗中的使用

    公开(公告)号:WO2015067713A1

    公开(公告)日:2015-05-14

    申请号:PCT/EP2014/073967

    申请日:2014-11-06

    IPC分类号: A61K38/17 A61P31/04

    摘要: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 1) and wherein: X 1 is a basic amino acid; X 2 is an aromatic amino acid; X 3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X 4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X 5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents. In other aspects of the invention agents and compositions of the invention may be used in conjunction with one or more additional active agents, such as antibiotics.

    摘要翻译: 本发明提供了用于治疗或预防受试者细菌感染的试剂或含有试剂的组合物,其中所述试剂包括:(i)包含PCNA相互作用基序和促进细胞的结构域的寡肽化合物 所述化合物的摄取,其中所述PCNA相互作用基序是X1X2X3X4X5(SEQ ID NO:1),其中:X1是碱性氨基酸; X2是芳香族氨基酸; X3是除芳香族氨基酸,甘氨酸(G)和脯氨酸(P)之外的不带电荷的氨基酸; X4是除脯氨酸(P)以外的任何氨基酸,酸性氨基酸或芳香族氨基酸; X5是碱性氨基酸或脯氨酸(P); 或(ii)包含编码(i)的寡肽化合物的序列的核酸分子。 在某些方面,本发明的试剂和组合物可以用作单一试剂。 在本发明的其它方面,本发明的药剂和组合物可以与一种或多种另外的活性剂如抗生素结合使用。

    DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION
    7.
    发明申请
    DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION 审中-公开
    作为HIV感染危险因素的DNA序列检测

    公开(公告)号:WO2013113000A2

    公开(公告)日:2013-08-01

    申请号:PCT/US2013/023451

    申请日:2013-01-28

    申请人: MONTAGNIER, Luc

    发明人: MONTAGNIER, Luc

    摘要: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.

    摘要翻译: 使用聚合酶链式反应和特异性引物鉴定疾病,病症或病症(例如由人类免疫缺陷病毒引起的那些)的风险因子的方法。 通过组合抗病毒和抗细菌治疗或通过维持或刺激受试者的免疫系统对风险因素进行抗微生物治疗来治疗患有这些疾病,病症或病症的患者的方法。 筛选包括红细胞制剂在内的生物制品的方法。 用于检测与红细胞有关的核酸或微生物试剂的引物和方法,例如在感染HIV并接受抗逆转录病毒疗法的受试者中与红细胞有关的那些试剂。

    TREATMENT OF BACTERIAL INFECTIOUS DISEASES
    9.
    发明申请
    TREATMENT OF BACTERIAL INFECTIOUS DISEASES 审中-公开
    治疗细菌感染性疾病

    公开(公告)号:WO2012034955A1

    公开(公告)日:2012-03-22

    申请号:PCT/EP2011/065701

    申请日:2011-09-12

    IPC分类号: A61K31/70

    摘要: The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.

    摘要翻译: 本发明涉及人类细菌感染性疾病的新型药理学治疗。 具体地说,本发明涉及式(I)的安普霉素或安普霉素衍生物在人体中治疗细菌感染性疾病的用途。 据证实,阿帕霉素令人惊讶地没有预期的相关氨基糖苷类抗生素观察到的高水平毒性,但实际上甚至比已用于人类药物(如庆大霉素)的化合物显着降低毒性。